Strategy to prevent epitope masking in CAR.CD19+ B-cell leukemia blasts.

ABSTRACT: Chimeric antigen receptor T-cells (CAR T-cells) for the treatment of relapsing/refractory B-cell precursor acute lymphoblastic leukemia have led to exciting clinical results. However, CAR T-cell approaches revealed a potential risk of CD19-/CAR+ leukemic relapse due to inadvertent transduction of leukemia cells.

Background

METHODS: We evaluated the impact of a high percentage of leukemia blast contamination in patient-derived starting material (SM) on CAR T-cell drug product (DP) manufacturing. In vitro as well as in vivo models were employed to identify characteristics of the construct associated with better profile of safety in case of inadvertent B-cell leukemia transduction during CAR T-cell manufacturing.

Results

The presence of large amounts of CD19+ cells

SUBMITTER: Quintarelli C 

PROVIDER: S-EPMC8211055 | biostudies-literature | 2021 Jun

REPOSITORIES: biostudies-literature